Premium
Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre‐/post‐study
Author(s) -
Manotham K.,
Ongvilawan B.,
Urusopone P.,
Chetsurakarn S.,
Tanamai J.,
Limkuansuwan P.,
Tungsanga K.,
EiamOng S.
Publication year - 2012
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1445-5994.2011.02610.x
Subject(s) - olmesartan , medicine , kidney disease , hypoxia (environmental) , kidney , angiotensin ii , urology , angiotensin receptor , oxygenation , endocrinology , cardiology , receptor , oxygen , blood pressure , chemistry , organic chemistry
Chronic intrarenal hypoxia has been regarded as a pathogenic factor of progressive renal damage. However, the lack of available human data has impeded the progress in this field. In this work, blood oxygen level‐dependent magnetic resonance imaging was used to determine intrarenal oxygen status pre‐ and post‐angiotensin receptor blockade (olmesartan) treatment in normal subjects, diabetic chronic kidney disease (CKD) patients and non‐diabetic CKD patients. The mean R 2 *, which represents intrarenal oxygenation, was significantly lower in the control group than in the CKD group (12.42 ± 0.53 /s vs 18.89 ± 3.15 /s, P < 0.01), indicating the presence of intrarenal hypoxia in the CKD patients. The olmesartan treatment induced a 16.2 ± 7.7% decrement of the mean R 2 * in CKD patients, suggesting that this drug had an intrarenal hypoxia ameliorating effect.